Organisation paid for research Program year 2025 Source: CMS Open Payments

Collier Neurologic Specialists

Neither a doctor nor a teaching hospital

Research payments

$3,179,438

125 payments

Through program year 2025, Collier Neurologic Specialists is reported as receiving $3,179,438 in research payments, across 125 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $528,988 4
2024 Research $572,464 2
2023 Research $387,332 4
2022 Research $869,604 25
2021 Research $346,163 17
2020 Research $177,768 14
2019 Research $297,118 59

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,236,155 18 payments
  2. Janssen Research & Development, LLC $305,739 24 payments
  3. Adamas Pharmaceuticals, Inc. $303,912 60 payments
  4. Ucb SA $267,151 3 payments
  5. Avanir Pharmaceuticals, Inc. $40,729 12 payments
  6. Regeneron Pharmaceuticals, Inc. $11,435 3 payments
  7. ACADIA Pharmaceuticals Inc $9,407 3 payments
  8. Biogen, Inc. $4,875 1 payment
  9. Merck Sharp & Dohme Corporation $35 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $1,754,057 9 payments
  2. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $464,373 5 payments
  3. A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease $305,739 24 payments
  4. A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study to Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment $242,023 42 payments
  5. A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal to Mild Alzheimers Disease (Ad), Followed By An Open-Label Extensio $201,335 1 payment
  6. A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment $61,889 18 payments
  7. A Patient- and Investigator-Blind, Placebo-Control $55,265 1 payment
  8. 15-Avp-786-303 $28,603 6 payments
  9. Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy $13,060 3 payments
  10. Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis $11,435 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record